The Impact of Melanoma and Drug Treatment in the Real World

Intratumoral Application of L19IL2 in Patients With Malignant Melanoma

NCT01253096 ·Status: COMPLETED ·Phase: PHASE2

Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma

NCT02902029 ·Status: COMPLETED ·Phase: PHASE2

Follow-up of a National Cohort of Melanoma Resectable Stage II, Stage III or IV Patients or Unresectable Primary

NCT02828202 ·Status: RECRUITING

Carboplatin and Temozolomide in Treating Patients With Unresectable or Metastatic Melanoma

NCT00003747 ·Status: UNKNOWN ·Phase: PHASE1

Study of First-line Treatment Patterns and Clinical Outcomes in Patients With Advanced Melanoma in the United Kingdom

NCT03448497 ·Status: COMPLETED

Investigating Participation Patterns Among Stage IV Melanoma Patients

NCT06093594 ·Status: NOT_YET_RECRUITING

Anti-CD20 (Cluster of Differentiation Antigen 20) Therapy to Treat Metastatic Melanoma

NCT01376713 ·Status: COMPLETED ·Phase: PHASE2

Head and Neck Melanoma; Access to Staging and Surgical Treatment

NCT05900102 ·Status: COMPLETED

Hepatic Arterial Infusion With Melphalan in Treating Patients With Unresectable Liver Cancer

NCT00030082 ·Status: COMPLETED ·Phase: PHASE1

CCI-779 in Treating Patients With Metastatic Melanoma

NCT00022464 ·Status: COMPLETED ·Phase: PHASE2

Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Locally Advanced Melanoma of the Arm or Leg

NCT00003789 ·Status: COMPLETED ·Phase: PHASE3

Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma

NCT00324727 ·Status: COMPLETED ·Phase: PHASE3

Buparlisib in Melanoma Patients Suffering From Brain Metastases (BUMPER)

NCT02452294 ·Status: UNKNOWN ·Phase: PHASE2

A Study is to Understand the Treatment Patterns for Immunotherapy Agents and BRAF/MEK Inhibitors Used in the Treatment of Advanced Melanoma

NCT03696069 ·Status: COMPLETED

Symptoms of Immune Checkpoint Inhibitor Therapy in Cutaneous Melanoma

NCT07148245 ·Status: RECRUITING

Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma

NCT00324155 ·Status: COMPLETED ·Phase: PHASE3

Trial of Pembrolizumab and Radiotherapy in Melanoma

NCT02562625 ·Status: TERMINATED ·Phase: PHASE2

Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver Metastases

NCT04812470 ·Status: COMPLETED ·Phase: PHASE1

Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Melanoma

NCT00040352 ·Status: RECRUITING

Real-world Evaluation of the Impact of Baseline Metastases on Clinical Outcomes Among BRAF Positive Metastatic Melanoma Patients

NCT05984615 ·Status: COMPLETED

Long-term Data Collection for Subjects in MDX-010 Studies

NCT00928031 ·Status: COMPLETED

Registry Protocol- Melphalan Percutaneous Hepatic Perfusion for the Treatment of Unresectable Hepatic Malignancy

NCT03266042 ·Status: UNKNOWN

GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma

NCT01245062 ·Status: COMPLETED ·Phase: PHASE3

Treatment Patterns and Outcomes in Participants With Advanced Melanoma in Germany Using a German Database

NCT05426239 ·Status: COMPLETED

Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver Metastases

NCT05903937 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1